APP下载

沙库巴曲缬沙坦对心衰患者心室重构及血清TNF-a、IL-33及ICAM-1水平的影响

2021-11-04韩青廖然张历

上海医药 2021年19期
关键词:库巴缬沙坦心室

韩青 廖然 张历

摘 要 目的:分析沙库巴曲缬沙坦对心衰患者心室重构及血清TNF-a、IL-33及ICAM-1水平的影响。方法:将61例心衰患者按随机数表方法分为对照组(n=30)和观察组(n=31)。对照组采取常规抗心衰药物治疗,观察组采用沙库巴曲缬沙坦治疗。治疗4周后,对比两组心室重构情况及血清TNF-a、IL-33及ICAM-1水平。结果:观察组治疗后IVST、LVPWT水平低于对照组,LVMI水平高于对照组(P<0.05);血清TNF-a、IL-33及ICAM-1水平均低于对照组(P<0.05)。结论:沙库巴曲缬沙坦能够降低心衰患者血清TNF-a、IL-33及ICAM-1水平,阻碍心脏重构。

关键词 沙库巴曲缬沙坦 心衰 心室重构 TNF-a IL-33 ICAM-1

中图分类号:R972.1; R541.61 文献标志码:B 文章编号:1006-1533(2021)19-0012-03

Effects of sacubitril valsartan on ventricular remodeling and serum levels of TNF-α, IL-33 and ICAM-1 in patients with heart failure

HAN Qing, LIAO Ran, ZHANG Li

(the First Department of Cardiovascular Medicinet, the First Peoples Hospital of Jiujiang City, Jiujiang 332000, China)

ABSTRACT Objective: To investigate the effects of sacubitril valsartan on ventricular remodeling and serum levels of TNF-a, IL-33 and intercellular cell adhesion molecule-1 (ICAM-1) in patients with heart failure. Methods: Sixty-one patients with heart failure were randomly divided into a control group (n=30) and an observation group (n=31). The control group was treated with routine anti-heart failure drugs, and the observation group was treated with sacubitril valsartan. Ventricular remodeling and serum levels of TNF-a, IL-33 and ICAM-1 were compared between the two groups four weeks after treatment. Results: After treatment, the levels of interventricular septal thickness (IVST), left ventricular posterior wall thickness (LVPWT), serum TNF-a, IL-33 and ICAM-1 were lower while the levels of left ventricular mass index (LVMI) were higher in the observation group than the control group (P<0.05). Conclusion: Sacubitril valsartan can decrease serum levels of TNF-a, IL-33 and ICAM-1 in the patients and block cardiac remodeling.

KEy wORDS sacubitril valsartan; heart failure; ventricular remodeling; TNF-a; IL-33; ICAM-1

心力衰竭主要因患者心臟在正常生理作用下出现收缩或舒张障碍,从而影响静脉回心血量正常排出,导致心脏血液淤积,动脉血液灌注不足,进而造成患者心脏不能满足人体新陈代谢需要[1]。随着人口老龄化的发展,我国心力衰竭发病率和死亡率逐渐升高,严重影响老年人群的生命健康[2]。临床中常见的治疗心力衰竭方案主要从强心、利尿、扩张血管等方面进行治疗[3]。本研究旨在分析沙库巴曲缬沙坦对心衰患者心室重构及血清肿瘤坏死因子-a(tumor necrosis factor-a, TNF-a)、白介素-33(interleukin-33, IL-33)及细胞间细胞黏附分子-1(intercellular cell adhesion molecule-1, ICAM-1)水平的影响,现报道如下。

1 资料与方法

1.1 一般资料

将2019年1月—2019年12月期间在我院就诊的61例心衰患者按随机数表方法分为对照组(n=30)和观察组(n=31)。对照组:男20例,女10例;年龄51~74岁,平均年龄(64.77±3.44)岁;病程2~5年,平均病程(3.65±1.02)年;其中扩张型心肌病患者9例,缺血性心肌病患者14例,高血压性心脏病7例。观察组:男17例,女14例;年龄53~77岁,平均年龄(65.78±3.57)岁;病程2.5~7年,平均病程(4.12±0.78)年;其中扩张型心肌病患者10例,缺血性心肌病患者13例,高血压性心脏病8例。两组一般资料相比无统计学差异(P>0.05),具可比性。所有患者均签署知情书。

猜你喜欢

库巴缬沙坦心室
采用沙库巴曲缬沙坦片治疗慢性心衰的临床效果及对后期住院频率的观察
芥末糖
跳伞极限运动摄影
沙库巴曲缬沙坦的药代动力学和药效学特点
房阻伴特长心室停搏1例
冠心病伴心力衰竭合并心房颤动的心室率控制研究
缬沙坦联合葛根素在早期2型糖尿病肾病治疗中的作用
『孙爷爷』谈心室为孩子上网撑起『保护伞』
缬沙坦与依那普利联合治疗肺心病心力衰竭的疗效观察
黄芪片联合缬沙坦治疗早期糖尿病肾病24例